Immutep Ltd
ASX:IMM
Immutep Ltd
ASX:IMM
Price:
0.44 AUD
Market Closed
Updated:
May 30, 2024
EV/S
Enterprise Value to Sales
Enterprise Value to Sales
1 639.6
Current
936.8
Median
7.1
Industry
Higher
than median
Higher
than industry value
Enterprise Value to Sales (EV/S) ratio is a valuation multiple that compares the enterprise value (EV) of a company to its revenues. The EV/S multiple gives investors a quantifiable metric of how to value a company based on its sales while taking account of both the company's equity and debt.
EV/S
=1 639.6
Enterprise Value
/
420.8m
Revenue
256.6k
All Countries
| Market Cap | EV/S | ||||
|---|---|---|---|---|---|
| AU |
|
Immutep Ltd
ASX:IMM
|
523.1m AUD | 1 639.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
274.7B USD | 5.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
162.3B USD | 7.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.6B USD | 10.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.4B USD | 7.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
134.5B AUD | 7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.1B USD | 3.5 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
57.9B USD | 9.3 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.2 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.8B USD | 3.8 | |
| KR |
|
Celltrion Inc
KRX:068270
|
36.7T KRW | 16.3 |
EV/S Forward Multiples
Forward EV/S multiple is a version of the EV/S ratio that uses forecasted revenue for the EV/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/S
104.1
2-Years Forward
EV/S
24.8
3-Years Forward
EV/S
2.4
You don't have any saved screeners yet
